US4393064A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process and composition for treatment of leukemia and process for preparing the same
Assignee: SRI International Inc
•
Filing: 1979-09-17
•
Granted: 1983-07-12
•
Expires: 1999-09-17
Abstract
Abstract A process and composition are provided employing 10-deazaminopterin for treating leukemia and ascites tumor.
Inventors
- 👤 Joseph I. DeGraw, Jr.
- 👤 Francis M. Sirotnak
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 13:32
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K9/02; A61P; A61P35/00; A61P35/02; C; C07; C07D; C07D475/00; C07D475/06; C07D475/08
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
49 words
A pharmaceutical composition in tablet form for treating leukemia or an ascites tumor comprising an amount within the range from about 0.1 to about 500 mg of 10-deazaminopterin per tablet therapeutically effective to ameliorate leukemia or the ascites tumor, together with a pharmaceutically acceptable nontoxic carrier or diluent therefor.
Claim 2
Dependent Claim
49 words
A pharmaceutical composition in tablet form for treating leukemia or an ascites tumor comprising an amount within the range from about 0.1 to about 500 mg of 10-deazaminopterin per tablet therapeutically effective to ameliorate leukemia or the ascites tumor, together with a pharmaceutically acceptable nontoxic carrier or diluent therefor.
Claim 3
Dependent Claim
22 words
A pharmaceutical composition according to claim 1 in which the 10-deazaminopterin is in the form of a pharmaceutically acceptable acid addition salt.
Claim 4
Dependent Claim
49 words
A pharmaceutical composition in capsule form for treating leukemia or an ascites tumor comprising an amount within the range from 0.1 to about 500 mg of 10-deazaminopterin per capsule therapeutically effective to ameliorate leukemia or the ascites tumor, together with a pharmaceutically acceptable nontoxic inert carrier or diluent therefor.
Claim 5
Dependent Claim
49 words
A pharmaceutical composition in capsule form for treating leukemia or an ascites tumor comprising an amount within the range from 0.1 to about 500 mg of 10-deazaminopterin per capsule therapeutically effective to ameliorate leukemia or the ascites tumor, together with a pharmaceutically acceptable nontoxic inert carrier or diluent therefor.
Claim 6
Dependent Claim
22 words
A pharmaceutical composition according to claim 3 in which the 10-deazaminopterin is in the form of a pharmaceutically acceptable acid addition salt.
Claim 7
Dependent Claim
50 words
A pharmaceutical composition in suppository form for treating leukemia or an ascites tumor comprising an amount within the range from about 0.1 to about 500 mg of 10-deazaminopterin per suppository therapeutically effective to ameliorate leukemia or the ascites tumor, together with a pharmaceutically acceptable nontoxic inert carrier or diluent therefor.
Claim 8
Dependent Claim
50 words
A pharmaceutical composition in suppository form for treating leukemia or an ascites tumor comprising an amount within the range from about 0.1 to about 500 mg of 10-deazaminopterin per suppository therapeutically effective to ameliorate leukemia or the ascites tumor, together with a pharmaceutically acceptable nontoxic inert carrier or diluent therefor.
Claim 9
Dependent Claim
22 words
A pharmaceutical composition according to claim 5 in which the 10-deazaminopterin is in the form of a pharmaceutically acceptable acid addition salt.
Claim 10
Dependent Claim
50 words
A pharmaceutical composition in cachet form for treating leukemia or an ascites tumor comprising an amount within the range from about 0.1 to about 500 mg of 10-deazaminopterin per cachet therapeutically effective to ameliorate leukemia or the ascites tumor, together with a pharmaceutically acceptable nontoxic inert carrier or diluent therefor.
Claim 11
Dependent Claim
50 words
A pharmaceutical composition in cachet form for treating leukemia or an ascites tumor comprising an amount within the range from about 0.1 to about 500 mg of 10-deazaminopterin per cachet therapeutically effective to ameliorate leukemia or the ascites tumor, together with a pharmaceutically acceptable nontoxic inert carrier or diluent therefor.
Claim 12
Dependent Claim
22 words
A pharmaceutical composition according to claim 7 in which the 10-deazaminopterin is in the form of a pharmaceutically acceptable acid addition salt.
Claim 13
Dependent Claim
51 words
A pharmaceutical composition in sterile aqueous form for treating leukemia or an ascites tumor comprising an amount within the range from about 0.1 to about 500 mg of 10-deazaminopterin therapeutically effective to ameliorate leukemia or the ascites tumor, together with a pharmaceutically acceptable nontoxic sterile inert aqueous carrier or diluent therefor.
Claim 14
Dependent Claim
51 words
A pharmaceutical composition in sterile aqueous form for treating leukemia or an ascites tumor comprising an amount within the range from about 0.1 to about 500 mg of 10-deazaminopterin therapeutically effective to ameliorate leukemia or the ascites tumor, together with a pharmaceutically acceptable nontoxic sterile inert aqueous carrier or diluent therefor.
Claim 15
Dependent Claim
22 words
A pharmaceutical composition according to claim 9 in which the 10-deazaminopterin is in the form of a pharmaceutically acceptable acid addition salt.
Claim 16
Dependent Claim
11 words
A pharmaceutical composition according to claim 9, in aqueous solution form.
Claim 17
Dependent Claim
11 words
A pharmaceutical composition according to claim 9, in aqueous dispersion form.
Claim 18
Dependent Claim
41 words
A process for treating leukemia and ascites tumors which comprises administering to a warm-blooded animal having an abnormal proportion of leukocytes or other evidence of the malignancy, a therapeutic and relatively nontoxic amount of 10-deazaminopterin, to ameliorate leukemia or ascites tumors.
Claim 19
Dependent Claim
41 words
A process for treating leukemia and ascites tumors which comprises administering to a warm-blooded animal having an abnormal proportion of leukocytes or other evidence of the malignancy, a therapeutic and relatively nontoxic amount of 10-deazaminopterin, to ameliorate leukemia or ascites tumors.
Claim 20
Dependent Claim
18 words
A process according to claim 13 in which the 10-deazaminopterin is administered as a pharmaceutically acceptable salt thereof.
Claim 21
Dependent Claim
27 words
A process according to claim 13 in which the 10-deazaminopterin is administered in an amount with the range from about 0.1 to about 500 mg per day.
Claim 22
Dependent Claim
18 words
A process according to claim 13 in which the 10-deazaminopterin is administered with an inert diluent or carrier.
Claim 23
Dependent Claim
13 words
A process according to claim 13 in which the 10-deazaminopterin is administered orally.
Claim 24
Dependent Claim
13 words
A process according to claim 13 in which the 10-deazaminopterin is administered parenterally.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-07-11 | 1987-01-10 | 1987-07-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-07-11 | 1991-01-10 | 1991-07-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-07-11 | 1995-01-10 | 1995-07-12 | $7700.00 | Window Closed / Lapsed |